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Summary 
Hepatitis C virus (HCV) reinfection rates are likely underestimated due to reinfection episodes 
occurring between study visits. A Markov model of HCV reinfection and spontaneous clearance was 
fitted to empirical data. Bayesian post-estimation was used to project reinfection rates, reinfection 
spontaneous clearance probability and duration of reinfection. Uniform prior probability distributions 
were assumed for reinfection rate (>0), spontaneous clearance probability (0-1) and duration (0.25-
6.00 months). Model estimates were 104 per 100 person-years(95%CrI:21-344), 0.84(95%CrI:0.59-
0.98), and 1.3 months(95%CrI:0.3-4.1) for reinfection rate, spontaneous clearance probability, and 
duration, respectively. Simulation studies were used to assess model validity, demonstrating that the 
Bayesian model estimates provided useful information about the possible sources and magnitude of 
bias in epidemiological estimates of reinfection rates, probability of reinfection clearance and duration 
or reinfection. The quality of the Bayesian estimates improved for larger samples and shorter test 
intervals. Uncertainty in model estimates notwithstanding, findings suggest that HCV reinfections 
frequently and quickly result in spontaneous clearance, with many reinfection events going 
unobserved.  
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1 Introduction 
The hepatitis C virus (HCV) infects an estimated 185 million people worldwide and is a significant 
cause of morbidity and mortality [1]. In high-income countries, people who inject drugs (PWID) are 
the subgroup at greatest risk of HCV infection [2]. Although approximately 25% will spontaneously 
clear their infection [3] and there have been major advances in HCV antiviral treatment [4], there is 
still no vaccine for HCV.  
Naturally acquired immunity to HCV is complex. Previous infection with HCV appears to confer only 
partial immunity from future HCV infection. In individuals who were re-exposed to HCV after 
successfully clearing an initial infection (primary infection), further infections (reinfection) have been 
documented. Reinfection with a new HCV infection can be distinguished from viral relapse of the 
initial HCV infection by viral sequencing [5-11]. HCV reinfection has been observed in two main 
population groups, both of which are characterised by repeated exposures to HCV: PWID [5-10, 12-
16] and HIV-infected men who have sex with men who engage in high-risk sexual behaviour 
[11, 17, 18].  
Longitudinal studies of HCV reinfection among PWID are relevant for HCV vaccine development 
because they give insights into acquired natural immunity to HCV. In particular, if it were possible to 
identify people in which naturally acquired immunity enabled spontaneous clearance after reinfection, 
the mechanism could be investigated and potentially mimicked in a vaccine [19]. To date, results from 
reinfection studies have varied considerably. Reinfection rates that are lower and higher to primary 
infection rates in the same populations have been reported [5, 7-10, 12-15, 20]. Furthermore, a broad 
range of spontaneous clearance probabilities have been reported (minimum reported value: 0.3, 
maximum reported value: 1.0) [7, 8, 10, 12-15, 20]. Although variations between populations in the 
rate of reinfection are expected (depending on the frequency of exposure to HCV), the probability of 
spontaneous clearance after reinfection is likely to be dependent on the natural immune response to 
HCV, and not only the frequency of exposure, and can therefore be expected to be more consistent 
between populations. 
We recently showed that variation in the study testing interval may account for much of the observed 
variation in HCV reinfection studies [21]. This is because reinfections that spontaneously clear can go 
undetected if the duration of the reinfection is shorter than the testing interval [22]. Ideally, short 
testing intervals (potentially shorter than one month) would be used to generate more reliable 
estimates of reinfection incidence and spontaneous clearance probability. However, it is challenging 
to follow PWID frequently. As a result, in this paper we explore an analytical method (Bayesian post-
estimation) for estimating the reinfection rate, reinfection duration and probability of reinfection 
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spontaneous clearance given study data that was collected at wider than optimal testing intervals. Data 
were from the Networks 2 prospective cohort study of PWID, which was a community-based study 
undertaken in Melbourne, Australia from 2005-2010 and had a median three-monthly testing interval 
[5, 15, 23]. 
Estimation of key quantities associated with reinfection occurrence and clearance is challenging given 
typical observational data.. In the context of data with test intervals that are on average greater than 
the duration of spontaneously-clearing reinfection, the parameters to be estimated are intimately 
linked. For example, it is possible that the observed data correspond with a relatively high reinfection 
rate and short duration of reinfection or a lower reinfection rate and a longer duration of reinfection. 
This makes it difficult to estimate all three parameters simultaneously. In this paper, in addition to 
investigating how precisely the parameter values can be estimated given the sparseness of available 
data, we also use simulation studies to test the method and investigate how short the testing interval 
would need to be in order to generate precise and accurate estimates for the parameters of interest: 
reinfection rate, reinfection duration and clearance probability.  
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2 Materials and Methods 
2.1 Participants and data collection 
The Networks 2 study was an observational cohort study of PWID in Melbourne, Australia [23]. 
Study participants were recruited from street illicit drug markets, as reported in detail elsewhere [23]. 
The main recruitment period was 2005-2006 and participants were followed until 2010. Participants 
were followed every three months. Participation was voluntary, and informed consent was obtained 
from each participant in writing. At each study visit, participants were bled and tested for anti-HCV 
antibodies and HCV RNA amongst other things. Ethical approval for the study was obtained from the 
Victorian Department of Human Health Research Ethics Committee (project 02/05). Study 
participants who did not report receiving HCV antiviral treatment and who were classified as being 
susceptible to reinfection (defined below) and then had at least one subsequent HCV RNA test at any 
point during the study were eligible for inclusion in these analyses. In total, 252 participants were 
enrolled in the study, 25% (n=64) were lost to follow-up and of the remaining 188 participants, 46 
were susceptible to reinfection (Figure 1). Laboratory methods are described in the Appendix. 
2.2 Study definitions 
2.2.1 HCV infection and clearance 
HCV infection and clearance classifications are illustrated in Figure 1. Participants who tested 
positive for HCV RNA were classified as being infected with HCV, regardless of anti-HCV status. 
Primary infection was defined by anti-HCV seroconversion. Participants were classified as 
susceptible to reinfection if they had evidence of spontaneous clearance of HCV infection. This was 
defined as either testing anti-HCV antibody positive and HCV RNA negative at two consecutive 
study visits (at least 28 days apart) or, after testing HCV RNA positive, testing HCV RNA negative 
and then HCV RNA positive where the second appearance of viraemia was genetically distinct from 
the first. Among those susceptible to reinfection, occurrences of intermittent viraemia – defined as at 
least one HCV RNA negative test followed by an HCV RNA positive test – were identified. Where 
possible, HCV viral sequence analysis was used to determine whether the new viraemia was 
genetically distinct from previous infections (detailed methods in the Appendix). A confirmed 
reinfection was classified as a new episode of HCV viraemia that was genetically distinct from the 
previous infection (detailed methods in the Appendix). Where it was not possible to assess whether 
the two instances of viraemia were genetically distinct because no sequencing data was available on 
the initial infection, the term possible reinfection was used. A possible reinfection was classified as a 
new episode of viraemia that occurred after at least two consecutive negative tests (at least 28 days 
apart to confirm spontaneous clearance) and was not possible to assess as being genetically distinct 
from the previous infection. All analyses were performed for confirmed reinfections only and 
confirmed and possible reinfections combined.  
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2.2.2 Date of first susceptibility to reinfection 
Data were included in these analyses from the first time that the participant was classified as 
susceptible to reinfection. For participants who were susceptible at study entry, this was the date of 
the baseline visit. For participants who were not susceptible at study entry, this was the first 
spontaneous clearance date (defined as the midpoint between the last HCV RNA positive test and the 
first HCV RNA negative test). For analyses that were limited to confirmed HCV reinfections, 
participants only became susceptible after clearing an infection where it was possible to sequence 
virus from the first infection. This meant that fewer participants were included in the confirmed 
reinfection analyses compared to the possible reinfection analyses.  
2.3 Estimates for parameter values calculated using a simple 
epidemiological approach 
The following are simple methods for estimating the parameter values that have commonly been used 
in epidemiological studies. The date of reinfection was defined as the midpoint between the date of 
the first HCV RNA positive test and the previous HCV RNA negative test. The date of spontaneous 
clearance was defined as the midpoint between the last HCV RNA positive test and the first HCV 
RNA negative test. Reinfection rates were taken as the total number of reinfection episodes observed 
(in some cases there were multiple episodes per participant) divided by the number of person-years 
that participants were susceptible to reinfection. Clearance probability was estimated by taking the 
proportion of reinfection episodes with at least two follow-up tests after the estimated date of 
reinfection that resulted in spontaneous clearance. Duration of infection was estimated based on those 
reinfection episodes that resulted in spontaneous clearance. In this study, the estimates computed 
using this approach were used as a comparison for the model-based estimates. 
2.4 Model description and assumptions 
HCV reinfection and spontaneous clearance were modelled as a homogenous Markov process 
consisting of three main states: susceptible (S), acute infection (IA), and chronic infection (IC) (Figure 
2). Because there is no blood test to distinguish acute from chronic infection, the transition between 
acute and chronic states was modelled as a hidden Markov process. The model was adapted from our 
previous probabilistic individual-based model of HCV reinfection and clearance [21]. Participants 
were classified as susceptible to reinfection if they had evidence of having previously cleared a HCV 
infection. Because the observational data were collected over a short time-frame (five years), it was 
assumed that those in the susceptible state became reinfected at a constant rate (α). Once reinfected 
participants moved to the acute infection state (IA). From the acute infection state, it was assumed that 
participants could spontaneously clear (with probability β ), thereby returning to the susceptible state, 
or their infection could progress to chronicity, state IC. The duration of a state with a constant exit rate 
is distributed exponentially. In order to ensure a plausible distribution for the duration of acute 
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reinfection (γ), acute infection was divided into two states (IA1  and IA2) and participants left each of 
these states at constant rates ቀଶ
ఊ
ቁ ; thus, while the duration of each of the two acute infection states 
followed an exponential distribution, the combination of the two member states effectively 
implements a realistic Gamma-distributed acute infection duration [24]. 
Thus, the per-month rate of spontaneous clearance was defined as the product of the spontaneous 
clearance probability and the per-month rate of leaving the second of these acute infection states ቀଶஒ
ஓ
ቁ, 
whereas the per-month rate of an infection progressing from the acute infection state to the chronic 
infection state was defined as the product of the chronic infection probability and the per-month rate 
of leaving the second of these acute infection states ቀଶሺଵିఉሻ
ఊ
ቁ . Those with chronic infection (state IC) 
were assumed to remain in that state indefinitely. Because it is not possible to distinguish acute 
infection from chronic infection based on laboratory data alone, the probability of being in the acute 
or chronic infection state given that a participant has evidence of infection was determined 
probabilistically (details in the Appendix). The per-month rates of reinfection and clearance were 
assumed to remain constant throughout and not to be dependent on the number of previous 
reinfections.  
The model is a continuous-time deterministic ordinary differential equation model. The instantaneous 
rates of change between states i and j are summarised in the following instantaneous rate matrix, Qij:  
  S  IA1  IA2  IC 
  S  −α α 0  0 
Q = 
IA1  0 
െ2
ߛ
2
ߛ
  0 
 
IA2 
2ߚ
ߛ
0 
െ2
ߛ
2ሺ1 െ ߚሻ
ߛ
  IC  0 0 0 0
 
The instantaneous rate matrix Q, has the property that, ௗ
ௗ௧
ࡼሺݐሻ ൌ ࡼሺtሻࡽ, which can then be solved to 
provide an equation for P(t), the transition pro l atrix at time, t:  babi ity m
ࡼሺݐሻ ൌ ݁௧ࡽ                                                     
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2.5 Model­based parameter estimation 
A Bayesian approach was used to estimate the unknown parameter values (reinfection rate, average 
duration of acute reinfection, and probability that a reinfection results in spontaneous clearance) from 
the study observations (Figure 3). In short, the Bayesian framework posits that the inferred probability 
distribution for the parameters of interest (called the posterior probability distribution and abbreviated 
to ‘posterior’) depends on both the study observations and some prior probabilities that have been 
assigned by the researchers. Prior probability distributions (‘priors’) are described below. Monte-
Carlo Markov chain (MCMC) methods were used to calculate a posterior probability distribution of 
the parameter set (θ={α,β,γ}) and posterior probability distributions for functions of those parameters 
(the latter are termed marginal posterior probability distributions and abbreviated to ‘marginal 
distribution’) [25]. Marginal distributions were also calculated for the proportion of participants with 
persistent infections (that is, in the chronic infection state) after 1,2,3,…, and 10 years. A detailed 
description of the approach taken, including derivation of transition probability matrices, likelihood 
calculations, and details of the MCMC methods are described in the Appendix. Point estimates from 
the Bayesian analysis are median posteriors; 95% credible intervals (CrI) were also calculated. 
Bayesian terminology are summarised in Supplementary Table 1. 
2.5.1 Assumptions and priors 
Uniform uninformative priors were assigned to the reinfection rate (α) and probability of spontaneous 
clearance (β). The reinfection rate was assumed to be greater than zero and clearance probability was 
assumed to be between 0 and 1. A uniform prior was assigned to the duration of acute reinfection (γ), 
where the average duration of acute reinfection was assumed to be greater or equal to seven days and 
less than six months (within this interval, all possible values for the duration of acute reinfection were 
considered equally likely). A six month maximum was imposed because it is known that the majority 
of primary infections that spontaneously clear do so within six months and observational studies have 
shown that reinfection is shorter than primary infection  [3, 7, 26]. A seven day minimum was 
imposed because this is the shortest reinfection duration that has been observed in chimpanzees; it 
was observed in three of nine chimpanzees who were reinfected with the same viral genotype as their 
primary infection [27].  
2.5.2 Likelihood calculations 
The likelihood of the observed data was calculated by taking the product of the probabilities of the 
observed state transitions (defined in section 2.4), and the observed state transitions.  Because it was 
not possible to determine whether an infected participant was in the acute state or the chronic state on 
the basis of the observed data, a hidden Markov model was used. The probability of observing a 
participant in an infected state was taken as the probability of the participant being in the acute 
infection state or the chronic infection state. Thus, if a participant tested anti-HCV antibody positive 
and HCV RNA positive at a given timepoint, and three months later they tested anti-HCV antibody 
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positive and HCV RNA positive again, the transition probability would be taken as the sum of all 
possible infected state to infected state transition probabilities – for example, the three month 
probability of transitioning from the first acute infection state to the first acute infection state, or 
transitioning from the first acute infection state to the second acute infection state, or transitioning 
from the acute infection states to the susceptible state and back to one of the acute infection states, etc. 
Formulae for calculating these probabilities are included in Supplementary Table 2. 
Note that according to the study definitions (described in detail below), a person is considered to 
move from the infected to susceptible state only on the basis of observing two consecutive negative 
tests or one negative test followed by a change in HCV genotype, subtype, or viral sequence. If a 
participant tested HCV RNA positive, then HCV RNA negative and then HCV RNA positive and 
there was no change in genotype , subtype or viral sequence, we conservatively classified them as 
being infected at all stages because it is possible that the HCV RNA negative result represented low 
levels of viraemia rather than viral clearance. However, if the final two tests for a given participant 
were HCV RNA positive followed by HCV RNA negative, the participant could not be classified as 
either having spontaneous clearance or low levels of viraemia. For this special case, the probability of 
moving from infected to susceptible or moving from infected to infected were both allowed, with the 
relative probabilities of each being defined by calculating the proportion of HCV RNA positive, HCV 
RNA negative sequences with at least one subsequent follow-up observation that went on to be 
classified as spontaneous clearances. 
Given that the HCV RNA test used (COBAS AMPLICOR 2.0) is highly sensitive (>96%), specific 
(>99%), and has a very low limit of detection (<50 IU/mL)[28], no measurement error was assumed 
for classification as infected (HCV RNA positive), or uninfected (two consecutive negative HCV 
RNA tests or one negative HCV RNA test followed by detection of a genetically distinct HCV virus 
in the subsequent test).   
2.6 Model adequacy and data requirements 
2.6.1 Evaluating model adequacy 
In order to investigate (a) the precision and accuracy of the model predictions given the sparseness of 
the observed data (i.e., three to four month test interval and an average of five follow-up tests per 
participant) and (b) how short the testing interval would need to be in order to estimate the primary 
quantities precisely, the model was tested on simulated data (Figure 3). Data similar to those collected 
in the Networks 2 study, but with variations in test interval and parameter values, were simulated 
using a continuous individual stochastic model with the same structure as the model depicted in 
Figure 2 above. The model simulations are described in detail in the Appendix, but briefly, simulated 
samples were produced using a two-stage process: first, values for the unobserved times of 
reinfections and clearances for each participant were produced for two different scenarios regarding 
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the assumed duration of acute reinfection, reinfection rate and probability of clearance, and three 
different scenarios regarding the number of participants (one scenario resembling the confirmed 
reinfections only dataset with 16 participants, one resembling the confirmed and possible reinfections 
dataset with 46 participants, and a further scenario with a larger group of 100 participants). Second, 
observed event occurrence indicators were generated, following an observation scheme that mimicked 
that used in actual studies. Four different test intervals (half, one, two and four months) were used. 
The target analysis was applied to each of the resulting simulated samples. Simulations consisted of 
100 repetitions of each sample, with each simulation representing a specified scenario with respect to 
the parameters of the model generating the actual event times, the chosen sample size, and the 
observation scheme (i.e., the test interval) In total, there were 2 (two reinfection duration, reinfection 
rate and probability of clearance scenarios) × 3 (low, medium or high numbers of participants) ×4 
(four test interval scenarios) = 24 scenarios simulated. (Figure 3 and Table 1).  
Each simulated sample was analysed using the same methods used to analyse the Networks 2 
observational study data to obtain estimates for the reinfection rate, clearance probability and duration 
of acute reinfection. The quality of the Bayesian model estimates derived using different test intervals 
was assessed against the characteristics of the simulated samples under perfect observation (Figure 3), 
and the median (95% credible interval) error was calculated across the 100 datasets.  
2.7 Software 
Study data were stored in MS Access and manipulated (including data cleaning and traditional 
statistical analysis) in Stata 11 (College Station, Texas 2011). All models were implemented in the R 
programming environment (version 2.13.1) [29]. 
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3 Results 
3.1 Analysis of observational data 
3.1.1 Simple epidemiological approach 
Forty-six participants were classified as susceptible to reinfection at some point during the study 
period, did not report having received antiviral therapy, and had at least one subsequent follow-up 
test. Eligible participants had a median of five follow-up tests after becoming susceptible to 
reinfection (interquartile range: 3-10) and participants were susceptible to reinfection for a total of 
106 person-years. Overall, nine confirmed reinfection events and 17 possible reinfection events were 
observed [5]. Estimates for reinfection rate, duration of acute reinfection and reinfection clearance 
probability calculated using the simple epidemiological approach are presented in Table 2. 
3.1.2 Model-based approach 
Model estimates for each of the parameters are presented in Table 2. Compared to estimates derived 
from epidemiological analyses, the model estimated reinfection rates were on average 3.5 (for 
confirmed reinfections only) – 2.5 (for confirmed and possible reinfections) times greater, but they 
lacked certainty with very wide 95% credible intervals (ranging from approximately 20 to over 200 
per 100 PY). The model-estimated reinfection durations were shorter than the estimates derived using 
the simple epidemiological approach (1-2 months compared to approximately 4 months for both 
reinfection classifications) but also had wide 95% credible intervals. The model estimates for 
spontaneous clearance probabilities were approximately 0.85-0.90 for both reinfection classifications 
(with credible intervals ranging from 0.59-0.98 for confirmed reinfections only, and 0.80-0.98 for 
confirmed or possible reinfections) – that is, on average, 50-70% greater than the epidemiological 
estimates. The model estimates for cumulative risk of persistent reinfection were 0.12 at 1 year, 0.52 
at 5 years, and 0.78 at 10 years for confirmed reinfections only (Figure 4). Results were similar for 
analyses of confirmed and possible reinfections.  
3.1.3 Relationships between parameters 
There was a strong inverse association between the model estimated reinfection rate and reinfection 
duration (Supplementary Figure 1). This is because based on the available data it was equally likely 
that there were a relatively large number of short reinfections or smaller numbers of long reinfections. 
For the same reason, there was also a weaker association between reinfection rate and clearance 
probability (Supplementary Figure 1).  
3.2 Analysis of simulated data 
3.2.1 Simple epidemiological approach 
Simulated samples were analysed using the naïve and Bayesian approaches defined above. Estimates 
derived from the simulated samples by applying the simple epidemiological approach were compared 
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to the characteristics of the simulated samples under perfect observation (Figure 3). The estimates 
were biased toward underestimating the reinfection rates and spontaneous clearance probabilities, 
while overestimating the reinfection durations. As expected, the magnitude of the bias decreased as 
the testing interval decreased (Figure 5 and Supplementary Figure 2).  
3.2.2 Model-based approach 
When compared to the characteristics of the simulated samples under perfect observation (Figure 3), 
the Bayesian model estimates were much more accurate than the estimates calculated using the simple 
epidemiological approach; however, the quality of these estimates varied by the model inputs used to 
produce the simulated samples, and the test interval (Table 1). Three primary parameters were 
estimated: reinfection rate, reinfection duration, and spontaneous clearance probability. Of these, 
reinfection rate was the most challenging to estimate accurately. Estimates for the reinfection duration 
were closer to those of the simulated samples under perfect observation (the median error was within 
1.2 months for all model scenarios) than were estimates for the reinfection rate (the median error 
ranged from approximately 0 to over 60 cases per 100 PY). Median model estimates for the 
spontaneous clearance probability were the most reliable of all the three parameters (the median error 
was less than 0.11 for all model scenarios).  
Estimates for all parameters improved as the ratio of test interval to duration of acute reinfection 
decreased. When the test interval was half the duration of acute reinfection, the model estimates were 
unbiased and precise. In contrast, the estimates calculated using the simple epidemiological approach 
remained inaccurate regardless of the test interval (Figure 5 and Supplementary Figures 2). Estimates 
for all parameters also improved as the number of participants increased from 16 to 46. Although they 
continued to improve as the number of participants increased from 46 to 100, the improvement was 
relatively small, with the most important factor influencing precision of estimates being the test 
interval once the number of participants was at least 46. For example, in the simulations with a model 
input mean duration of reinfection of one month, when the test interval is 0.5 months, the credible 
interval for the error in reinfection rate was close to ±30 cases per 100 person-years with both 46 
participants and 100 participants. Similarly, the credible interval for reinfection duration error was 
within approximately ± 0.5 months, and the credible interval for the error in probability of 
spontaneous clearance was approximately ± 0.05 regardless of whether there were 46 or 100 
participants. In contrast, estimates were less precise when only 16 participants were modelled, and 
were biased when the test interval was greater than the average duration of reinfection. 
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4 Discussion 
The aim of this study was to investigate the HCV reinfection rate, probability of spontaneous 
clearance in reinfection and duration of reinfection from a sparse dataset with a three-month testing 
interval. A hidden Markov infection transition model was fitted using Bayesian post-estimation. 
Simulation studies were used to test the method and investigate data requirements for future studies. 
Findings indicated that HCV reinfections have a high spontaneous clearance probability. The duration 
of HCV reinfection is likely to be short relative to primary infection and HCV reinfections are likely 
to occur very frequently, but additional data is required to confirm these findings. Simulation study 
findings highlighted the importance of frequency of testing in observational studies of HCV 
reinfection for producing unbiased and precise estimates of reinfection-related parameters. This 
methodology is not just useful for investigating HCV reinfection, but can also be applied to other 
infectious diseases for which reinfection or asymptomatic recurrences are difficult to discern 
clinically but important epidemiologically; including Chlamydia, HSV-2 and tuberculosis [30-33].  
The approach used in this paper provides important insights into the process of reinfection and 
clearance for the Melbourne Network study. The spontaneous clearance probability was estimated to 
be about 0.85-0.90 using the hidden Markov infection transition model; this compares to a simple 
epidemiological estimate of approximately 0.50-0.60. The main difference between the two estimates 
is that the simple epidemiological estimate assumes that the reinfections that have been observed are 
representative of all reinfections in the study population whereas the model-based estimate accounts 
for the fact that spontaneously clearing reinfections are less likely to be observed because they may 
fall between study visits. The hidden Markov infection transition model estimate in particular is very 
high (much higher than the spontaneous clearance probability in primary infection – approximately 
0.25 [3, 26]), suggesting that either HCV infection confers partial acquired immunity against future 
persistent infection even if there is no immunity against future self-limiting infection, or that 
individuals who clear primary HCV infection have characteristics that protect them from HCV 
infections. This is consistent with a previous observational study that found that within eight 
individuals, the duration of primary infection tended to be longer than the duration of reinfection and 
the spontaneous clearance probability was high [7]. This finding has implications for vaccine 
development, suggesting that it may be possible to develop a vaccine that protects against persistent 
HCV infection.  
The ‘simple epidemiological’ approach that has been used in this paper as a comparison for the 
model-based approach has been used in many epidemiological studies of HCV reinfection (for 
example, [7, 9, 10, 12, 15]). However, more complex approaches are available and have been used in 
some studies. Kaplan-Meier survival times have be used to estimate the proportion of reinfections that 
are self-limiting in the context of censored data, where participants may clear after having been lost to 
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follow-up or after the study is completed [20]. A number of Cox-like regression methods are available 
for investigating factors associated with the hazard of recurrent events [34], and some have been used 
in the context of HCV reinfection [5]. However, these methods do not account for the possibility that 
some (or many) of the reinfections are likely to have been missed in between study visits. Methods 
that incorporate interval censoring can be used to account for intermittent sampling when participants 
drop out of the study and re-enter [20]. However, even these methods are not appropriate for the 
situation where events can be missed in between any two study visits, even when participants attend 
regularly. The problem of estimating recurrent event data from length-biased samples has been 
recognised previously. Cook and Lawless provide a bibliography of research in this area and 
distinguish two types of situations in which participants in recurrent event studies are sampled only 
intermittently during follow-up [35]. In the first, the number of events and the times at which they 
occurred can be ascertained retrospectively – for example, if participants keep diaries of the events as 
they occur but only present to study personnel intermittently. In the second case, the number of events 
can be ascertained retrospectively but the timing cannot – for example, tumors that are detected using 
medical imaging technologies. In the context of HCV reinfection, the situation is even more complex 
in that neither the number of events that have been missed nor the event times can be ascertained 
retrospectively. In this study, a hidden Markov infection transition model was used to estimate HCV 
reinfection rates, durations and spontaneous clearance probabilities given that reinfections were likely 
missed between study visits. 
All analyses were undertaken for both confirmed reinfections only and a combination of confirmed 
and possible reinfections. Confirmed reinfections represent the gold-standard, whereas analyses that 
include possible reinfections may be subject to misclassification errors, where some transient 
fluctuations in viral load may have been classified as possible reinfections. This has been shown to 
occur after more than six months of sustained viraemia [8, 36], but is rare after 10 weeks of 
undetectability (as occurred for all spontaneous clearances in the Networks 2 study) making 
misclassification unlikely but still possible in the data used here. With respect to the reinfection 
duration estimates, the slightly longer durations estimated when including possible reinfections as 
well as confirmed reinfections may be due to such misclassification errors. Indeed, longer reinfection 
durations and reduced precision were observed when possible reinfections were included in addition 
to confirmed reinfections. However, limiting the analyses to confirmed reinfections resulted in fewer 
participants and reinfection events. Including two scenarios for the number of the participants in the 
simulated samples demonstrated that model estimates were more accurate and precise when applied to 
larger data sets. Ideally, when sufficient data exist, the modelling approach outlined here would be 
applied to a larger data set of confirmed reinfections only. Such a data set would include at least 40-50 
participants who have spontaneously cleared a previous HCV infection. Given that approximately 
25% of primary HCV infections clear spontaneously and assuming an attrition rate of 25%, 
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approximately 215-265 participants with primary HCV infection would need to be followed in order 
to identify a sufficient number of participants to study for reinfection (a large but realistically 
achievable cohort).  
As expected, the simulation studies indicate that greater precision can be achieved by increasing the 
number of participants, or increasing the frequency of testing, demonstrating that the model developed 
is likely to produce more reliable estimates if applied to a greater quantity of data. However, once the 
number of participants was >46, increases in the number of participants resulted in only relatively 
small increases in precision compared to increases in the frequency of testing. Simulation results 
indicate that ideally the test interval should be around half the average duration of reinfection; 
however, in practice the average duration of reinfection is unknown. This raises the question of how 
short the test interval needs to be. In an observational study, if the test interval is greater than the 
duration of spontaneously clearing reinfections then at best there will only be one HCV RNA positive 
test for each reinfection. As the test interval decreases, approaching or becoming less than the 
reinfection duration, the likelihood of having two positive tests for each reinfection increases. This 
can be illustrated using the simulated data (Figure 6). While it is not a guarantee that the test interval 
is sufficiently short, aiming for two positive tests in at least one third of spontaneously clearing 
reinfections could be used as a rule of thumb for assessing whether the frequency of testing is 
sufficient. This has been achieved in one study with a one month testing interval, where four of 10 
spontaneously clearing reinfections had two viraemic timepoints (Table 3). Although the number of 
events is small, this may indicate that a one month test interval is sufficiently short.  
Future work could apply and validate this model with larger datasets. Indeed, one of the advantages of 
the Bayesian methods used in this study is that they allow incremental refinement of results as more 
information is accrued. Specifically, the posterior estimates of this study could be used as prior 
probabilities for future studies with similar design. In this way, study information can be pooled to 
improve the utility of the data and increase the precision of estimates. In addition, reinfection rates in 
a variety of contexts and populations can be inferred and compared without needing to spend valuable 
resources following each population equally frequently. In some cases, where the population of 
interest is difficult to follow frequently, this is not only a matter of efficient use of resources but 
allows reinfection rates to be measured where otherwise this would not be possible. 
Estimating the timing and frequency of events that can occur between study visits is not only relevant 
to HCV, but also to a range of other infectious diseases. Asymptomatic reinfection with chlamydia, 
gonorrhoea, malaria, tuberculosis and pertussis among other infections, is common and potentially 
relevant to disease transmission and pathogenesis [30-33]. In the context of chlamydia infection, 
modelling studies have shown that asymptomatic reinfections occurring between chlamydia tests can 
affect epidemiological estimates of chlamydia duration, incidence and prevalence [37], and can also 
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make retesting policies ineffectual if most reinfections occur earlier than people commonly present for 
retesting [38]. Herpes simplex virus (HSV) (particularly type 2) has periods of asymptomatic viral 
recurrence. HSV-2 asymptomatic viral shedding occurs frequently and is thought to be crucial for 
onward transmission of the virus [39, 40]. HIV viral load is also an important predictor of HIV 
transmission, which has become very topical recently in the context of HIV antiretroviral treatment 
being used to prevent HIV transmission [41]. Estimating the frequency and duration of viral 
breakthrough (that is a detectable HIV viral load) when on antiretroviral treatment is important for 
understanding transmissibility in the era of antiretrovirals. The methods presented in this paper can be 
adapted to studying these (and other) examples of asymptomatic reinfection and/or viral recurrence. 
 
4.1 Limitations: 
The model includes a number of simplifying assumptions. We did not test the validity of the infection 
transition model (Figure 2) and the superiority of our methods compared to the simple 
epidemiological approach can only be taken in the context of this assumption. The model constructed 
however, is based on the current understanding of the biology of HCV and can account for the 
observations of changing infection status. Whether reinfection rates or clearance probabilities change 
after multiple reinfections is unknown (only very few cases of multiple consecutive infection have 
been reported [7, 8]); therefore, we assumed that the rate of reinfection and clearance probability were 
constant over time. Further, it is not known whether heterologous exposure to different HCV 
genotypes affects spontaneous clearance of HCV reinfection, so the issue of cross-genotype protection 
was not addressed. Finally, we have previously shown that reinfection rates differ by injecting risk 
[15], and a number of studies have shown that gender, IL28B genotype, and other host factors affect 
spontaneous clearance in primary HCV infection [42-44]. However, because our analysis already 
involved inferring three parameters (reinfection rate, reinfection duration and clearance probability), 
on the basis of 26 observed confirmed or possible reinfection events, we did not include additional 
complexity but assumed similar reinfection rates and reinfection duration for all participants. While 
we did allow for random variation in the times to reinfection and clearance events, which will have 
accounted for some of the variation in rates of infection and clearance, when sufficient data exist 
ideally future studies will investigate the effect of these confounding factors.  
In addition to limitations associated with model assumptions, observational data were drawn from a 
convenience sample of PWID, so results cannot necessarily be generalised. The sample was recruited 
from street-based illicit drug markets and participants reported relatively risky injecting behaviour, so 
they are likely to represent a high risk population for HCV acquisition [23]. Finally, analyses 
presented here were repeated for confirmed reinfections only and for confirmed and possible 
reinfections. As discussed in more detail above, the analyses that included possible reinfections are 
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subject to misclassification errors and the analyses that included confirmed reinfections only are 
limited by the small quantity of data.  
Finally, whereas under observational study conditions test intervals vary between and within 
participants, the simulated samples were produced using fixed test intervals. However, additional 
simulations (not shown) including random variability in test interval length showed it did not affect 
results. 
5 Conclusions 
In this paper, we presented an analytical method for estimating HCV reinfection rates and related 
measures that provides useful information about possible sources and magnitude of bias in estimates 
of reinfection rates, probability of reinfection clearance and duration or reinfection.  Model estimates 
suggested that spontaneous clearance probability is high. Our findings suggest that the duration of 
spontaneously clearing reinfection is about one month; however, this result needs to be confirmed 
with additional data. In order to produce precise estimates, observational study data with test interval 
equal to or shorter than the duration of reinfection is required. This method can also be applied to 
other diseases with asymptomatic reinfection and/or viral recurrence.  
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10 Figure Legends 
Figure 1: Flowchart of reinfection classifications 
Figure 2: Model diagram 
Legend: S: susceptible to reinfection; IA1 and IA2: acute reinfection; IC: chronic reinfection.  
હ: per month probability of reinfection=rate of reinfection in reinfections per person-month; ઺: 
probability that a reinfection will result in spontaneous clearance; ઻: average duration of acute 
reinfection  
Figure 3: Schematic showing how Bayesian postestimation is used on the 
real Networks data to estimate unknown parameters, and on simulated 
data with known parameters to assess model adequacy. 
Legend: The true values of the three parameters of interest (reinfection rate, reinfection duration and 
reinfection spontaneous clearance probability) are unknown in the Networks study sample and in the 
population from which study participants were recruited (grey shaded region signifies unknown). 
However, for the simulated data, the model inputs and resulting characteristics of the simulated 
samples under perfect observation are known and can be compared to the Bayesian postestimates and 
the simple epidemiological estimates in order to assess their accuracy, and evaluate how that is related 
to different factors.  
Figure 4: Model estimated risk of persistent reinfection in the Networks 
study after 1-10 years for (a) confirmed and possible reinfections; and 
(b) confirmed reinfections only. 
Legend: All results are reported as median (95% CrI)  
Figure 5: Estimates and errors for reinfection rate, duration of 
reinfection and spontaneous clearance, by test interval for the simulated 
observational data: traditional epidemiological methods compared to 
model-based approach.  
Legend: Grey: estimates calculated using model-based approach. Blue: estimates calculated using 
traditional epidemiological methods. Horizontal dotted lines indicate ‘true’ inputs. Model inputs: 
mean reinfection duration=1 month (median duration=0.8 months), reinfection duration modelled 
using a gamma distribution with the variance equal to 0.5 months. Mean reinfection rate=109 per 100 
PY. Time to reinfection modelled using an exponential distribution with mean time to reinfection 
equal to the inverse of the mean rate of reinfection, and variance equal to the inverse of the mean rate 
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of reinfection squared. Reinfection clearance probability=0.93. Errors are relative to the 
characteristics of the simulated samples under perfect observation. Horizontal dotted lines in the 
estimate plots indicate ‘true’ inputs, horizontal dotted lines in the error plots indicate no error 
(error=0). 
Figure 6: The percent of self-limiting reinfections with at least two HCV 
RNA positive tests in simulated data 
Legend: Simulated datasets with 100 participants. 
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11 Electronic Supplementary Material – titles and legends 
Appendix 1 and Supplementary Tables 
Supplementary Figure 1: Relationships between parameters from 
posterior distribution – Networks study data 
Legend: (a) Reinfection rate as a function of reinfection duration. (b) Reinfection rate as a function of 
the per month rate of spontaneous clearance. (c) Spontaneous clearance percent as a function of 
reinfection rate. (d) Spontaneous clearance percent as a function of the average time between 
reinfections.  
Supplementary Figure 2: Estimates and errors for reinfection rate, 
duration of reinfection and spontaneous clearance, by test interval for 
the simulated observational data: traditional epidemiological methods 
compared to model-based approach.  
Legend: Grey: estimates calculated using model-based approach. Blue: estimates calculated using 
traditional epidemiological methods. Horizontal dotted lines indicate ‘true’ inputs. Model inputs: 
mean reinfection duration=2 month (median=1.6 months), reinfection duration modelled using a 
gamma distribution with the variance equal to 2 months. Mean reinfection rate=72 per 100 PY. Time 
to reinfection modelled using an exponential distribution with mean time to reinfection equal to the 
inverse of the mean rate of reinfection, and variance equal to the inverse of the mean rate of 
reinfection squared. Reinfection clearance probability=0.89. Errors are relative to the characteristics 
of the simulated samples under perfect observation. Horizontal dotted lines in the estimate plots 
indicate ‘true’ inputs, horizontal dotted lines in the error plots indicate no error (error=0). 
Supplementary Figure 3: Convergence diagnostics – MCMC analysis of 
Networks study data 
Legend: Plots of the MCMC samples in the order they were drawn and their autocorrelation.  
values are printed at the bottom of each page of plots. 
Supplementary Figure 4: Convergence diagnostics – MCMC analysis of 
simulated data 
Legend: Plots of the MCMC samples in the order they were drawn and their autocorrelation.  
values are printed at the bottom of each page of plots. Plots are included for the first five repetitions of 
each simulation scenario. 
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12 Tables 
Table 1: Details of the first group of simulations: simulations to test model adequacy 
 Number of 
scenarios 
Details 
Reinfection duration, reinfection rate and 
clearance probabilitya 
2 Scenario 1:  
• Mean duration=1 month 
• Mean rate=109 per 100 PY 
• Clearance probability=0.93 
 
Scenario 2:  
• Mean duration=2 month 
• Mean rate=72 per 100 PY 
• Clearance probability=0.89 
Number of participants 3 16, 46, 100 
Test interval 4 ½, 1, 2, 4 months  
Repetitions 100  
Total number of simulations 2400 2×3×4×100 
aReinfection duration is modelled using a gamma distribution with variance equal to 0.5 and 2 for 
scenarios 1 and 2, respectively. Time to reinfection is modelled using an exponential distribution with 
mean time to reinfection equal to the inverse of the mean rate of reinfection, and variance equal to the 
inverse of the mean rate of reinfection squared. 
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Table 2: Estimates calculated using the simple epidemiologicalapproach and model-based approach 
for reinfection rate, duration of acute reinfection and reinfection clearance probability for the 
Networks 2 study 
  Confirmed reinfections 
only 
Confirmed and possible 
reinfections 
Data characteristics:   
- Reinfection cases (n) 9 26 
- Person-years at risk of reinfection 
(PY) 
31 106 
- Clearance episodes (n) 4 13 
Simple epidemiological parameter 
estimates: 
  
- Reinfection rate (cases per 100 PY) 28.8 (15.0-55.4) 24.6 (16.8-36.1) 
- Reinfection clearance probability 0.50 (0.16-0.84) 0.59 (0.36-0.79) 
- Duration of acute reinfection 
(months) 
3.5 (2.5-11.2) 4.1 (3.0-7.7) 
Bayesian model parameter estimates:   
- Reinfection rate (cases per 100 PY) 104.1 (21.1-344.1) 61.7 (25.0-231.3) 
- Reinfection clearance probability 0.84 (0.59-0.98) 0.90 (0.80-0.98) 
- Duration of acute reinfection 
(months) 
1.3 (0.3-4.1) 2.5 (0.3-5.2) 
Note: Simple epidemiological parameter estimates for reinfection rate and reinfection clearance 
probability are reported as mean (95% confidence interval); these are calculated based on the 
assumption that all reinfection events are independent and for consistency with model estimates, do 
not account for within person correlations. Estimates of reinfection clearance probability are 
calculated excluding events where there was no subsequent follow-up. Simple epidemiological 
estimates for duration of acute reinfection are reported as median (IQR). All model estimates are 
reported as median (95% credible interval). PY: person-years.  
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Table 3: The percentage of spontaneous clearing reinfections that have multiple viraemic time points 
reported in published literature and in this study, by test interval.  
Test 
interval 
(months) 
Study Spontaneously 
clearing 
infections 
(confirmed) – n 
Confirmed 
infections 
with multiple 
viraemic time-
points – n (%) 
Spontaneously 
clearing 
infections 
(confirmed or 
possible) – n 
Confirmed or 
possible 
infections with 
multiple 
viraemic time-
points – n (%) 
1 Osburn 
2010 [7] 
10 4 (40) 10 4 (40) 
Page 2013 
[8] 
2 0 (0) 2 0 (0) 
Total 12 4 (33) 12 4 (33) 
3 Grebely 
2012 [6] 
1 0 (0) 2 0 (0) 
Networks 
study  
4 1 (25) 13 3 (23) 
Total 5 1 (20) 15 3 (20) 
6 Micallef 
2007 [14] 
2 1 (50) 3 1 (33) 
van de 
Laar 2009 
[10] 
0 0 (N/A) 3 0 (0) 
Total 2 1 (50) 6 1 (17) 
 
